Union Securities To Act As Lead Underwriter For The Millenia Hope Biopharma Financing

MONTREAL, QC, and WILMINGTON, DE, Dec. 7 /PRNewswire-FirstCall/ - Millenia Hope Biopharma Inc. is pleased to announce today that its affiliated company, Millenia Hope Biopharma (MHB), has concluded an agreement to retain Union Securities Ltd, a national securities firm, to act as its sponsor and underwriter for the following: A 10 million convertible debenture, interest rate of 10% per annum, and including assisting MHB with a public listing on the TSX.

ABOUT MILLENIA HOPE INC & MILLENIA HOPE BIOPHARMA:

The company has put in place programs to fight major infectious diseases and promote healthier lives and is committed to research and development to deliver on global medical needs and to bring hope through healthcare solutions. Founded in 1997 the company has initially focussed on the need to bring safe and affordable herbal therapies to market for major third world diseases such as malaria and HIV. The first product in this series is MMH(TM)Malarex / MMH(TM)18,. Millenia is also pursuing inhibitors of HIV RNase H (patent application pending). Successful development of a drug that targets HIV RNase H will play an important role in the treatment of HIV/AIDS patients who have become resistant to current therapy. www.milleniahope.com

Millenia Hope Biopharma (MHB) a related company to MHI, founded in 1998, is the world's leading bioresearch firm in Phytomics Technologies, commercializing plant cell-based bioprocesses for the discovery, development and production of natural and novel plant-derived products for the pharmaceutical, cosmetic and nutraceutical industries. MHB has spent over US $25 million in developing its unique proprietary Phytomics Technologies, including the world's largest collection of highly purified phytochemical fractions to be utilized in the pharmaceutical, cosmetic and nutraceutical industry. MHB also provides a plant based drug discovery platform designed for High Throughput Screening and is currently working with a number of leading multinational corporations such as Pierre Fabre Medicaments. www.mh-b.com

SAFE HARBOR STATEMENTS:

Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts, and expectations of Holley Pharmaceuticals Company Inc. that may be referred to as "forward- looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements and Holley Pharmaceuticals Company Inc. could encounter unanticipated obstacles and delays in developing products, services and markets.

CONTACT: Mr Leonard Stella, CEO, Millenia Hope Inc., (514) 846-5757,leostella@milleniahope.com